In a recent video interview with Applied Clinical Trials, Rob DiCicco, vice president of portfolio management at ...
Protocol design does not struggle in the protocol. It struggles in the transition to trial, when assumptions embedded in the ...
In today's ACT Brief, we examine what the FDA's real-time oversight initiative demands of sponsors, why clinical data ...
In today's ACT Brief, we examine quantified reductions in trial visits through selective safety data collection, why protocol ...
In today's ACT Brief, we examine a major trial retraction and regulatory action against a rare disease drug, regulatory scenarios for selective safety data collection, and FDA's domestic manufacturing ...
In this video interview, Rob DiCicco, vice president of portfolio management at TransCelerate Biopharma, explains why scaling pragmatic and decentralized trial approaches, not just piloting them once, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results